Status:
COMPLETED
Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This trial is conducted in Europe. The aim of the trial is to investigate the effect of NNC 90-1170 (liraglutide) on weight and appetite in obese subjects with type 2 diabetes treated with diet and/or...
Eligibility Criteria
Inclusion
- Type 2 diabetes mellitus
- Diet treated and/or subjects in monotherapy with sulphonylurea or repaglinide
- HbA1c for diet treated subjects 6.5-12%, both inclusive
- HbA1c for sulphonylurea or repaglinide treated subjects maximum 10%
- Body mass index (BMI) at least 27 kg/m\^2
- Euthyroid subjects
- Fasting blood glucose 7-14 mmol/l
Exclusion
- Impaired liver function
- Impaired renal function
- Cardiac problems
- Uncontrolled treated/untreated hypertension
- Recurrent severe hypoglycaemia as judged by the Investigator
- Known or suspected allergy to trial product or related products
- Use of any drug (except for OHAs (oral hypoglycaemic agents), which in the Investigator's opinion could interfere with the glucose level or body weight. Stable doses, for 3 months or greater, of thyroid hormone replacement are allowed
Key Trial Info
Start Date :
June 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2002
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT01508949
Start Date
June 1 2001
End Date
March 1 2002
Last Update
November 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Frederiksberg C, Denmark, 1958